|
| 36332179 | Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. | J Clin Oncol | 2023 |
| 37529369 | Augmented Reality in Breast Surgery Education. | Breast Care (Basel) | 2023 |
| 37523663 | Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey. | Oncologist | 2023 |
| 37556775 | Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. | J Clin Oncol | 2023 |
| 37479706 | Obesity-associated changes in molecular biology of primary breast cancer. | Nat Commun | 2023 |
| 37541279 | Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups. | Lancet Oncol | 2023 |
| 37133584 | Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. | N Engl J Med | 2023 |
| 37225592 | Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort. | Breast | 2023 |
| 37027797 | ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology. | JCO Oncol Pract | 2023 |
| 36934671 | In Honor of Hans-Jörg Senn. | Breast | 2023 |
| 36867773 | Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer. | Br J Radiol | 2023 |
| 36828834 | PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. | NPJ Breast Cancer | 2023 |
| 36861085 | Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. | Ther Adv Med Oncol | 2023 |
| 36928234 | Correction: Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study. | JMIR Form Res | 2023 |
| 34038908 | 3D Breast Volume Estimation. | Eur Surg Res | 2022 |
| 35839583 | Anthracyclines in the treatment of early breast cancer friend or foe? | Breast | 2022 |
| 35569438 | Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. | Eur J Cancer | 2022 |
| 35487836 | Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082]. | Ann Oncol | 2022 |
| 35355694 | Expert Discussion: Highlights from ABC6: Bridging the Gap and Insights in This First Virtual ABC Conference and from 10 Years ABC Consensus. | Breast Care (Basel) | 2022 |
| 36474966 | Associations between Physical Exercise, Quality of Life, Psychological Symptoms and Treatment Side Effects in Early Breast Cancer. | Breast J | 2022 |
| 36580360 | Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study. | JMIR Form Res | 2022 |
| 36686129 | Prevalence of Imaging-Detected Silent Female Breast Cancer in Autopsy Specimens: A Study Using Image-Guided Biopsies. | Cureus | 2022 |
| 36279803 | Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. | Breast | 2022 |
| 35870420 | Progression-free survival and quality of life in metastatic breast cancer: The patient perspective. | Breast | 2022 |
| 35927391 | The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. | NPJ Breast Cancer | 2022 |
| 36084384 | Current and future burden of breast cancer: Global statistics for 2020 and 2040. | Breast | 2022 |
| 36375387 | Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer. | Breast | 2022 |
| 34953404 | The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective. | ESMO Open | 2022 |
| 34861376 | Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. | Ann Oncol | 2022 |
| 35131646 | Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial. | Breast | 2022 |
| 35313167 | Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. | Eur J Cancer | 2022 |
| 34852292 | Quality-of-life methodology in hormone receptor-positive advanced breast cancer: Current tools and perspectives for the future. | Cancer Treat Rev | 2022 |
| 35061525 | Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. | J Clin Oncol | 2022 |
| 34995105 | Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). | J Clin Oncol | 2022 |
| 35139274 | Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. | N Engl J Med | 2022 |
| 34965945 | Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. | Clin Cancer Res | 2022 |
| 32912619 | Erratum to "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology 30; 2019: 1194-1220. | Ann Oncol | 2021 |
| 33548617 | Breast cancer surgery with augmented reality. | Breast | 2021 |
| 33716637 | Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8-11, 2020. | Breast Care (Basel) | 2021 |
| 33721561 | 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. | Lancet Oncol | 2021 |
| 34515408 | The Porto European Cancer Research Summit 2021. | Mol Oncol | 2021 |
| 34390999 | Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. | Breast | 2021 |
| 33991601 | Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria. | Ann Oncol | 2021 |
| 34183353 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. | Cancer Discov | 2021 |
| 34156869 | Gaps in Care and Support for Patients With Advanced Breast Cancer: A Report From the Advanced Breast Cancer Global Alliance. | JCO Glob Oncol | 2021 |
| 34312396 | Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. | NPJ Breast Cancer | 2021 |
| 34082017 | Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. | Ann Oncol | 2021 |
| 34191200 | Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer. | Breast Cancer Res Treat | 2021 |
| 33461060 | Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto. | Breast | 2021 |
| 33360479 | Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. | Breast | 2021 |